Language

English

Publication Date

9-1-2023

Journal

Pediatric Blood & Cancer

DOI

10.1002/pbc.30565

PMID

37449925

PMCID

PMC10577684

PubMedCentral® Posted Date

9-1-2024

PubMedCentral® Full Text Version

Author MSS

Abstract

Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children' Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.

Keywords

Young Adult, Child, Humans, Lymphoma, Non-Hodgkin, Lymphoma, Histiocytosis, Langerhans-Cell, Morbidity, Medical Oncology, Non-Hodgkin lymphoma, Langerhans cell histiocytosis, clinical trial, pediatric oncology

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.